Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and GSK have promised to supply 30 million doses each for the next 10 years. The first 20 percent of the supply will be sold for $7 per dose, while the remaining supply of Pfizer's Prevenar 13 and GSK's Synflorix will be sold for $3.50.
You may also be interested in...
ACIP's Support Of FDA-Approved Prevnar 13 Creates Opportunity For Larger Market
FDA approves Pfizer's Prevnar 13 vaccine and ACIP's recommendations set the stage for a broadened indication and a blockbuster product.
GSK Opens First Asian Vaccine Manufacturing Plant In Singapore
HONG KONG - Fifty years after it first started operating in Singapore, GlaxoSmithKline opened its first primary vaccine manufacturing facility in Asia in Singapore June 9
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.